No Detail Found!

PREVIDA: THE IMPACT OF VORTIOXETINE ON MAJOR DEPRESSIVE DISORDER AND PERCEIVED COGNITIVE DYSFUNCTION - A MULTICENTRE STUDY

Author(s)
ALI AHSAN MUFTI Jinnah Medical College, Peshawar and Ibadat Hospital Peshawar, Pakistan
HUMA MUGHAL Department of Psychiatry, Hayatabad Medical Complex,Peshawar, Pakistan
MUKHTAR UL HAQ AZEEMI Medical Teaching Institute Lady Reading Hospital Peshawar, Pakistan
MUHAMMAD ASIF KAMAL Department of Psychiatry,Gajju Khan Medical College,Swabi, Pakistan
FAZAL E RABBANI Department of Psychiatry, Lady Reading Hospital Peshawar,, Pakistan
KHALID ATTAULLAH MUFTI Ibadat Hospital, Peshawar,Pakistan
SYED MUHAMMAD SULTAN Syed Psychiatric Clinic, Peshawar, Pakistan
BASHIR AHMAD Department Of Psychiatry, Khyber Teaching Hospital, Peshawar,Pakistan
ZAINAB NAWAZ Department of Psychiatry,Gajju Khan Medical College,Swabi, Pakistan
ADIL AFRIDI Department of Psychiatry,Gajju Khan Medical College,Swabi, Pakistan
FATIMA AMIR KHAN Department of Behavioural Sciences/Psychiatry, Wah Medical College, OF College, Wah Cantt,Pakistan
MUHAMMAD FAHIM QASIM Department of Behavioural Sciences/Psychiatry, Wah Medical College, OF College, Wah Cantt,Pakistan
SHAKIL ASIF Benazir Bhutto Shaheed Medical College, Mirpur, Azad Jammu Kashmir, Pakistan
SYED USMAN HAMDANI HDRF Centre for Global Mental Health, Rawalpindi, Pakistan
AYESHA MINHAS Shifa Tamir e Millat University, Global Institute Of Human Development,Pakistan
FAREED ASLAM MINHAS Tree House Psychiatry Clinic, Rawalpindi, Pakistan.
Abstract
OBJECTIVE To find out how common cognitive impairment is in people with major depressive disorder (MDD) and assess how well vortioxetine works for treating both cognitive dysfunction and depressive symptoms. STUDY DESIGN Multi-centre, Cross-sectional, prospective follow up design PLACE & DURATION OF STUDY The research took place over the course of 12 weeks at 16 different psychiatric outpatient clinics throughout Pakistan, from September 2020 to November 2020. METHOD The study included 498 individuals with serious depressive disorder diagnoses. The degree of depression symptoms and cognitive impairment was assessed. Psychiatrists gave trial participants vortioxetine after completing the Clinical Global Impression-Severity scale (CGI-S), the Patient Health Questionnaire-9 (PHQ-9), and the Perceived Deficits Questionnaire (PDQ). The variables were reassessed one week (+/- 3 days), one month (+/- 7 days), and three months (+/- 14 days) after the treatment began. RESULTS After completing a 12-week course of therapy with vortioxetine, mean PHQ 9 and PDQ scores of MDD individuals showed significant improvements. This indicates that vortioxetine is effective in reducing depression symptoms as well as cognitive impairments in MDD patients. A strong connection was seen between PHQ-9 and PDQ scores, indicating a direct relationship between cognitive impairment and depressed symptoms. CONCLUSIONS The results of the research demonstrate how well vortioxetine works to treat cognitive impairments in MDD patients while also reducing depressed symptoms. These findings demonstrate the possibility of vortioxetine as a beneficial therapeutic option for those with MDD diagnoses who also have cognitive impairment. Additional investigation is required to validate these findings and assess their suitability for other demographics.
Publication Details
Page(s) 10-14
DOI DOI not available
Published Journal: Journal of Pakistan Psychiatric Society, Volume: 20, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
Vortioxetine, Impairment, Treatment Efficacy, Prospective study., Major depressive disorder (MDD)
0

Citations

0

Downloads

58

Views